Home › Compare › PPLFY vs ABBV
PPLFY yields 4.10% · ABBV yields 3.06%● Live data
📍 PPLFY pulled ahead of the other in Year 2
Combined, PPLFY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PPLFY + ABBV for your $10,000?
PT Perusahaan Perkebunan London Sumatra Indonesia Tbk, together with its subsidiaries, engages in the plantation business in Indonesia. The company operates through Oil Palm Products, Rubber, Seeds, and Other Product segments. It offers crude palm oil, rubber, cocoa, tea, and oil palm seeds. The company also develops plantations on behalf of local smallholders. As of December 31, 2021, it had a total planted area of 114,111 hectares comprising 93,853 hectares of palm oil; 16,228 hectares of rubber; and 4,030 hectares of cocoa, tea, and other crops in North Sumatra, South Sumatra, East Kalimantan, North Sulawesi, South Sulawesi, and Java. The company is also involved in the research, processing, trading, marketing, industrial, and agency/representative activities; and invests in agricultural technology and cultivation, as well as agriculture, forestry, and fishery businesses. It exports its products. The company was founded in 1906 and is headquartered in Jakarta Selatan, Indonesia. PT Perusahaan Perkebunan London Sumatra Indonesia Tbk is a subsidiary of PT Salim Ivomas Pratama Tbk.
Full PPLFY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.